製品名:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

CAS番号:90213-66-4
分子式:C6H3Cl2N3
純度:98%
カタログ番号:CM103618
分子量:188.01

包装単位 有効在庫 価格(USD) 数量
CM103618-100g in stock ʼnNJ
CM103618-500g in stock ůůŹ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:90213-66-4
分子式:C6H3Cl2N3
融点:-
SMILESコード:ClC1=NC(Cl)=C2C=CNC2=N1
密度:
カタログ番号:CM103618
分子量:188.01
沸点:
MDL番号:MFCD08059278
保管方法:-20°C

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

Capivasertib
On November 16, FDA approved Capivasertib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer. Capivasertib is a highly selective inhibitor targeting three AKT subtypes (AKT1/2/3), which can block signals used by cancer cells for division and growth.